Nanobiotix S.A.

NASDAQ:NBTX

Biotechnology

Healthcare
$26.90 -0.91%

-$0.33 today

Market cap
$1.37B
Beta
0.59
P/E (TTM)
-60.2
EPS (TTM)
-$0.51
52W Low $4.31High $57.14

Volume 0.04M

Average 0.08M

NBTX Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Nanobiotix S.A.NASDAQ: NBTX

Net Income · Q4 FY2025 · quarter ended Dec 2025

Net income declines year over year

Q4 FY2025 net income of €18.58M (cash outflow) fell 59.8% year over year. Over 3 fiscal years it compounded at -25.1% a year.

Context

  • Net income amounted to 80.8% of revenue in FY2025.
  • Net income grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 3 analysts of -€25.54M (+6.6%) for the fiscal year ending Dec 2026, a step up from the -64.8% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterDec 2025
-€18.58M— QoQ
Last fiscal yearDec 2025
-€23.96M-64.8% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-59.8%——
1 year-64.8%+6.6%+71.4 pp
3-year CAGR-25.1%——
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

EUR · from the cash flow

Latest · FY2025
(23.96M) EUR
Year-over-year change
+64.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How NBTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -64.8% is the 10th highest of 11, against a peer median of +36.7%.
  • Net income amounts to 80.8% of revenue for NBTX, versus a peer median of 261.6%.
NBTX Competitors
Net Income for NBTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IBRXImmunityBio, Inc.LTM Sep 2026$1.11B USD+218.3%-5.5%607.8%
KURAKura Oncology, Inc.LTM Mar 2026$294.57M USD+62.0%+27.1%411.2%
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$243.25M USD-26.6%+24.1%112.0%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$145.24M USD+14.0%+65.2%—
TYRATyra Biosciences, Inc.LTM Mar 2026$131.11M USD+36.0%+29.4%—
CADLCandel Therapeutics, Inc.LTM Mar 2026$54.42M USD+37.5%+26.7%—
BDTXBlack Diamond Therapeutics, Inc.LTM Mar 2026$43.21M USD-948.8%——
IMMXImmix Biopharma, Inc.LTM Mar 2026$34.98M USD+67.3%+52.9%—
NVCTNuvectis Pharma, Inc.LTM Mar 2026$29.59M USD+46.8%+11.5%—
PBYIPuma Biotechnology, Inc.LTM Mar 2026$24.38M USD-35.9%+2396.3%10.7%
NBTXNanobiotix S.A.FY2025€23.96M EUR-64.8%-25.1%80.8%
Peer median (excluding NBTX) —+36.7%+27.1%261.6%

Competitors are the stored peer set for NBTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(47M)(57.04M)(39.7M)(68.13M)(23.96M)
Depreciation & Amortization1.56M1.5M1.51M1.62M1.5M
Deferred Income Tax00003K
Stock-Based Compensation3.2M3.17M3.3M4.3M3.54M
Change in Working Capital(4.7M)(606K)(367K)131K(3.4M)
Accounts Receivables62K(101K)(806K)(2.07M)1.85M
Inventory00000
Accounts Payables00000
Other Working Capital(4.76M)(505K)439K2.2M(5.25M)
Other Non-Cash Items17.07M15.87M22.78M42.53M(11.1M)
Operating Cash Flow(29.87M)(37.1M)(12.48M)(19.55M)(33.42M)
Capital Expenditures(228K)(92K)(328K)(846K)(546K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities(14K)230K(21K)(109K)(40K)
Investing Cash Flow(242K)138K(349K)(955K)(578K)
Debt Repayment(3.74M)(4.74M)(3.62M)(4.16M)38.19M
Common Stock Issued00001.54M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(1.44M)(916K)50.39M(980K)(2.31M)
Financing Cash Flow(5.18M)(5.65M)46.77M(5.14M)37.42M
Effect of Forex Changes64K83K(51K)94K(402K)
Net Change in Cash(35.23M)(42.53M)33.9M(25.55M)3.01M
Free Cash Flow(30.1M)(37.2M)(12.8M)(20.4M)(33.97M)

Nanobiotix S.A.

NASDAQ:NBTX

Intrinsic Alpha fair value

Locked

Current Price

$26.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.